{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:30:34Z","timestamp":1790836234423,"version":"4.1.0"},"reference-count":136,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T00:00:00Z","timestamp":1572912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Classical Hodgkin Lymphoma (cHL) is a B-cell malignancy that, typically, responds well to standard therapies. However, patients who relapse after standard regimens or are refractory to induction therapy have a dismal outcome. The implementation of novel therapies such as the anti-CD30 monoclonal antibody Brentuximab Vedotin and immune checkpoint inhibitors has provided curative options for many of these patients. Nonetheless, responses are rarely durable, emphasizing the need for new agents. cHL is characterized by a unique microenvironment in which cellular and humoral components interact to promote tumor survival and dissemination. Knowledge of the complex composition of cHL microenvironment is constantly evolving; in particular, there is growing interest in certain cell subsets such as tumor-associated macrophages, myeloid-derived suppressor cells and neutrophils, all of which have a relevant role in the pathogenesis of the disease. The unique biology of the cHL microenvironment has provided opportunities to develop new drugs, many of which are currently being tested in preclinical and clinical settings. In this review, we will summarize novel insights in the crosstalk between tumor cells and non-malignant inflammatory cells. In addition, we will discuss the relevance of tumor-microenvironment interactions as potential therapeutic targets.<\/jats:p>","DOI":"10.3390\/ijms20215503","type":"journal-article","created":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T06:47:57Z","timestamp":1572936477000},"page":"5503","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma"],"prefix":"10.3390","volume":"20","author":[{"given":"Eleonora","family":"Calabretta","sequence":"first","affiliation":[{"name":"Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, 20089 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"d\u2019Amore","sequence":"additional","affiliation":[{"name":"Department of Haematology, Aarhus University Hospital, 8200 Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3144-0124","authenticated-orcid":false,"given":"Carmelo","family":"Carlo-Stella","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, 20089 Milano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Rozzano, 20089 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,11,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood-2015-08-665505","article-title":"Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution","volume":"127","author":"Kenderian","year":"2016","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11864-017-0483-z","article-title":"Clinical impact of the 2016 update to the WHO lymphoma classification","volume":"18","author":"Lynch","year":"2017","journal-title":"Curr. Treat. Options. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1182\/blood.V95.4.1443.004k55_1443_1450","article-title":"Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription","volume":"95","author":"Marafioti","year":"2000","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/ijc.30473","article-title":"The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis","volume":"140","author":"Carbone","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1182\/blood-2012-09-454694","article-title":"Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: Correlative analysis from a large North American cooperative group trial","volume":"121","author":"Kanakry","year":"2013","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2017-09-772632","article-title":"Biology of classical Hodgkin lymphoma: Implications for prognosis and novel therapies","volume":"131","author":"Mottok","year":"2018","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model","volume":"97","author":"Moskowitz","year":"2001","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.2009.07727.x","article-title":"Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma","volume":"146","author":"Moskowitz","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjh.12582","article-title":"Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma","volume":"164","author":"Collins","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1200\/JCO.2016.66.4466","article-title":"Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory hodgkin lymphoma: Final results of a multicenter phase II study","volume":"34","author":"Santoro","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/path.4558","article-title":"Primary refractory and early-relapsed Hodgkin\u2019s lymphoma: Strategies for therapeutic targeting based on the tumour microenvironment","volume":"237","author":"Carbone","year":"2015","journal-title":"J. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.canlet.2015.10.007","article-title":"Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance","volume":"380","author":"Aldinucci","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2010.32.8401","article-title":"Molecular pathogenesis of Hodgkin\u2019s lymphoma: Increasing evidence of the importance of the microenvironment","volume":"29","author":"Steidl","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1189\/jlb.3MR0315-136R","article-title":"The role of T cells in the microenvironment of Hodgkin lymphoma","volume":"99","author":"Wein","year":"2016","journal-title":"J. Leukoc. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1038\/leu.2014.201","article-title":"The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing","volume":"28","author":"Liu","year":"2014","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1182\/blood-2004-12-4750","article-title":"From Hodgkin disease to Hodgkin lymphoma: Biologic insights and therapeutic potential","volume":"105","author":"Re","year":"2005","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1182\/blood-2013-06-508044","article-title":"Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells","volume":"122","author":"Greaves","year":"2013","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood-2003-07-2594","article-title":"Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma","volume":"103","author":"Marshall","year":"2004","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/eji.1830260533","article-title":"T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding","volume":"26","author":"Huard","year":"1996","journal-title":"Eur. J. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2006-04-015164","article-title":"Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients","volume":"108","author":"Gandhi","year":"2006","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood-2018-04-843714","article-title":"Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment","volume":"132","author":"Cader","year":"2018","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1158\/1078-0432.CCR-04-1869","article-title":"Outcome in Hodgkin\u2019s lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells","volume":"11","author":"Alvaro","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/hon.878","article-title":"Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma","volume":"27","author":"Schreck","year":"2009","journal-title":"Hematol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1182\/blood.V82.4.1247.1247","article-title":"Hodgkin\u2019s lymphoma-derived tissue serially transplanted into severe combined immunodeficient mice","volume":"82","author":"Kapp","year":"1993","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/jcp.37.7.767","article-title":"Reed-Sternberg\/lymphocyte rosette: Lymphocyte subpopulations as defined by monoclonal antibodies","volume":"37","author":"Morris","year":"1984","journal-title":"J. Clin. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Tudor, C.S., Bruns, H., Daniel, C., Distel, L.V., Hartmann, A., Gerbitz, A., and Buettner, M.J. (2014). Macrophages and dendritic cells as actors in the immune reaction of classical Hodgkin lymphoma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0114345"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/ni.1937","article-title":"Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm","volume":"11","author":"Biswas","year":"2010","journal-title":"Nat. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin\u2019s lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/JCO.2011.39.9881","article-title":"Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome","volume":"31","author":"Greaves","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hon.2295","article-title":"Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin\u2019s lymphoma","volume":"35","author":"Gotti","year":"2017","journal-title":"Hematol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/annonc\/mdr157","article-title":"Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin\u2019s lymphoma","volume":"23","author":"Azambuja","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.leukres.2013.03.021","article-title":"Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma","volume":"37","author":"Casulo","year":"2013","journal-title":"Leuk. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/hon.2249","article-title":"Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment","volume":"35","author":"Cencini","year":"2017","journal-title":"Hematol. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1309\/AJCP61TLMXLSLJYS","article-title":"CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma","volume":"141","author":"Klein","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1158\/1078-0432.CCR-18-1133","article-title":"Targeting cancer cells and tumor microenvironment in preclinical and clinical models of hodgkin lymphoma using the dual PI3K\u03b4\/\u03b3 inhibitor RP6530","volume":"25","author":"Locatelli","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.4049\/jimmunol.181.8.5791","article-title":"Subsets of myeloid-derived suppressor cells in tumor-bearing mice","volume":"181","author":"Youn","year":"2008","journal-title":"J. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00262-012-1294-5","article-title":"Neutrophils and granulocytic myeloid-derived suppressor cells: Immunophenotyping, cell biology and clinical relevance in human oncology","volume":"61","author":"Dumitru","year":"2012","journal-title":"Cancer Immuno. Immunother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev-med-051013-052304","article-title":"Regulation of tumor metastasis by myeloid-derived suppressor cells","volume":"66","author":"Condamine","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6562","DOI":"10.4049\/jimmunol.0803831","article-title":"IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients","volume":"182","author":"Mandruzzato","year":"2009","journal-title":"J. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.coi.2010.01.021","article-title":"Myeloid-derived suppressor cell heterogeneity and subset definition","volume":"22","author":"Peranzoni","year":"2010","journal-title":"Curr. Opin. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00262-011-1028-0","article-title":"Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13","volume":"60","author":"Gabitass","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e2014039","DOI":"10.4084\/mjhid.2014.039","article-title":"Immunological deregulation in classic hodgkin lymphoma","volume":"6","author":"Romano","year":"2014","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"27676","DOI":"10.18632\/oncotarget.8507","article-title":"Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients","volume":"7","author":"Marini","year":"2016","journal-title":"Oncotarget"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.celrep.2014.12.039","article-title":"Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer","volume":"10","author":"Sagiv","year":"2015","journal-title":"Cell Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0092-8674(00)00139-2","article-title":"MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis","volume":"103","author":"Coussens","year":"2000","journal-title":"Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nm.2084","article-title":"Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth","volume":"16","author":"Houghton","year":"2010","journal-title":"Nat. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.imbio.2013.06.003","article-title":"Tumor associated macrophages and neutrophils in cancer","volume":"218","author":"Galdiero","year":"2013","journal-title":"Immunobiology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1126\/science.aaf7300","article-title":"CANCER. How neutrophils promote metastasis","volume":"352","year":"2016","journal-title":"Science"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1309\/AJCPO46GFKGNXCBR","article-title":"Prognostic significance of the ratio of absolute neutrophil count to absolute lymphocyte count in classic Hodgkin lymphoma","volume":"138","author":"Koh","year":"2012","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/hon.2359","article-title":"Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients","volume":"35","author":"Marcheselli","year":"2017","journal-title":"Hematol. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.cell.2019.05.047","article-title":"Neutrophils driving unconventional T cells mediate resistance against murine sarcomas and selected human tumors","volume":"178","author":"Ponzetta","year":"2019","journal-title":"Cell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41586-019-1118-2","article-title":"Fatty acid transport protein 2 reprograms neutrophils in cancer","volume":"569","author":"Veglia","year":"2019","journal-title":"Nature"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/hon.2900110404","article-title":"Infiltration of eosinophils in Hodgkin\u2019s disease involved lymph nodes predicts prognosis","volume":"11","author":"Enblad","year":"1993","journal-title":"Hematol. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood.V95.4.1207.004k34_1207_1213","article-title":"Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin\u2019s disease, allowing for known prognostic factors","volume":"95","author":"Seth","year":"2000","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/ejh.12583","article-title":"Tumour-associated mast cells in classical Hodgkin\u2019s lymphoma: Correlation with histological subtype, other tumour-infiltrating inflammatory cell subsets and outcome","volume":"96","author":"Andersen","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/ejh.12747","article-title":"The role of tumour-infiltrating eosinophils, mast cells and macrophages in classical and nodular lymphocyte predominant hodgkin lymphoma in children","volume":"97","author":"Englund","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1600-0609.2011.01652.x","article-title":"Predictors of histology, tissue eosinophilia and mast cell infiltration in Hodgkin\u2019s lymphoma--a population-based study","volume":"87","author":"Glimelius","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3389\/fimmu.2018.00267","article-title":"Acquired natural killer cell dysfunction in the tumor microenvironment of classic hodgkin lymphoma","volume":"9","author":"Chiu","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood.V64.2.386.386","article-title":"Association of an interleukin abnormality with the T cell defect in Hodgkin\u2019s disease","volume":"64","author":"Ford","year":"1984","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF01742314","article-title":"Impairment in proliferation, lymphokine production and frequency distribution of mitogen-responsive and interleukin-2-producing cells in Hodgkin\u2019s disease","volume":"34","author":"Damle","year":"1991","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bjc.1995.354","article-title":"Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2","volume":"72","author":"Gooding","year":"1995","journal-title":"Br. J. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2017-07-796342","article-title":"Immune evasion via PD-1\/PD-L1 on NK cells and monocyte\/macrophages is more prominent in Hodgkin lymphoma than DLBCL","volume":"131","author":"Vari","year":"2018","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cncr.11511","article-title":"A pilot study of rituximab in patients with recurrent, classic Hodgkin disease","volume":"98","author":"Younes","year":"2003","journal-title":"Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2012-01-405456","article-title":"Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma","volume":"119","author":"Younes","year":"2012","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.3324\/haematol.2018.199844","article-title":"ABVD plus rituximab","volume":"104","author":"Strati","year":"2019","journal-title":"Haematologica"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S1470-2045(17)30103-1","article-title":"Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin\u2019s lymphoma treated with BEACOPP","volume":"18","author":"Borchmann","year":"2017","journal-title":"Lancet. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/0046-8177(90)90047-9","article-title":"Vimentin immunostaining in fibroblastic reticulum cells within human reactive and neoplastic lymphoid follicles","volume":"21","author":"Gloghini","year":"1990","journal-title":"Hum. Pathol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1080\/10428190410001683633","article-title":"Interactions between tissue fibroblasts in lymph nodes and Hodgkin\/Reed-Sternberg cells","volume":"45","author":"Aldinucci","year":"2004","journal-title":"Leuk. Lymphoma."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3389\/fimmu.2018.01358","article-title":"Hodgkin lymphoma-derived extracellular vesicles change the secretome of fibroblasts toward a CAF phenotype","volume":"9","author":"Reiners","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: Implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41375-018-0178-x","article-title":"Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas","volume":"33","author":"Anastasiadou","year":"2019","journal-title":"Leukemia"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Zhou","year":"2018","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1182\/blood.V87.9.3844.bloodjournal8793844","article-title":"Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and -negative Hodgkin\u2019s disease","volume":"87","author":"Oudejans","year":"1996","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells","volume":"125","author":"Reichel","year":"2015","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.semcancer.2007.07.005","article-title":"Immune-refractory cancers and their little helpers--an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E?","volume":"17","author":"Wischhusen","year":"2007","journal-title":"Semin. Cancer Biol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.2006.10.0917","article-title":"HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin\u2019s lymphoma","volume":"25","author":"Diepstra","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1084\/jem.20031080","article-title":"c-FLIP mediates resistance of Hodgkin\/Reed-Sternberg cells to death receptor-induced apoptosis","volume":"199","author":"Mathas","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.celrep.2017.04.010","article-title":"Caspase-10 Negatively Regulates Caspase-8-Mediated Cell Death, Switching the Response to CD95L in Favor of NF-\u03baB Activation and Cell Survival","volume":"19","author":"Horn","year":"2017","journal-title":"Cell Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3109\/10428199909058456","article-title":"Expression of Fas and Fas ligand in Hodgkin\u2019s disease","volume":"33","author":"Metkar","year":"1999","journal-title":"Leuk. Lymphoma."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/annonc\/9.suppl_5.S21","article-title":"Immune escape mechanisms in Hodgkin\u2019s disease","volume":"9","author":"Poppema","year":"1998","journal-title":"Ann. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.4049\/jimmunol.177.8.5328","article-title":"Galectin-1 binds different CD43 glycoforms to cluster CD43 and regulate T cell death","volume":"177","author":"Hernandez","year":"2006","journal-title":"J. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1182\/blood-2006-04-016451","article-title":"Galectin-1: A key effector of regulation mediated by CD4+CD25+ T cells","volume":"109","author":"Chu","year":"2007","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1182\/blood-2007-01-066100","article-title":"Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma","volume":"110","author":"Gandhi","year":"2007","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"6638","DOI":"10.1182\/blood-2010-12-327346","article-title":"Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed\/refractory disease in classical Hodgkin lymphoma","volume":"117","author":"Kamper","year":"2011","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1182\/blood-2012-12-474569","article-title":"Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma","volume":"121","author":"Ouyang","year":"2013","journal-title":"Blood"},{"key":"ref_99","first-page":"274","article-title":"Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin\u2019s lymphoma","volume":"86","author":"Vassilakopoulos","year":"2001","journal-title":"Haematologica"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1158\/0008-5472.CAN-05-3252","article-title":"Prostaglandin E2 impairs CD4+ T cell activation by inhibition of lck: Implications in Hodgkin\u2019s lymphoma","volume":"66","author":"Chemnitz","year":"2006","journal-title":"Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1158\/2326-6066.CIR-17-0325","article-title":"Complex Immune Evasion Strategies in Classical Hodgkin Lymphoma","volume":"5","author":"Wein","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1200\/JCO.2006.10.1386","article-title":"Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin\u2019s lymphoma","volume":"25","author":"Sieniawski","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2013.49.8246","article-title":"Relapsed hodgkin lymphoma in older patients: A comprehensive analysis from the German hodgkin study group","volume":"31","author":"Goergen","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: Extended follow-up of the multicohort single-arm phase II checkmate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/2159-8290.CD-17-1033","article-title":"CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1\/PD-L1 Blockade","volume":"8","author":"Chen","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic hodgkin lymphoma: Safety and efficacy in the phase II checkmate 205 study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Armand, P., Chen, Y.B., Redd, R.A., Joyce, R.M., Bsat, J., Jeter, E., Merryman, R.W., Coleman, K.C., Dahi, P.B., and Nieto, Y. (2019). PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation. Blood.","DOI":"10.1182\/blood.2019000215"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Chen, R., Gibb, A.L., Collins, G.P., Popat, R., El-Sharkawi, D., Burton, C., Lewis, D., Miall, F.M., Forgie, A., and Compagnoni, A. (2017, January 14\u201317). Blockade of the PD1 Checkpoint with anti-PD-L1 antibody Avelumab is sufficient for clinical activity in Relapsed\/refractory Classical Hodgkin Lymphoma (CHL). Proceedings of the International Conference on Malignant Lymphoma, Lugano, Switzerland.","DOI":"10.1002\/hon.2437_54"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2008-07-168468","article-title":"CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation","volume":"113","author":"Bashey","year":"2009","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/path.1725","article-title":"Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin\u2019s lymphoma cells through a mechanism involving Akt kinase and mTOR","volume":"205","author":"Dutton","year":"2005","journal-title":"J. Pathol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/blood-2011-10-386763","article-title":"PI3K\u03b4 inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma","volume":"119","author":"Meadows","year":"2012","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/annonc\/mdx028","article-title":"Phase II study of idelalisib, a selective inhibitor of PI3K\u03b4, for relapsed\/refractory classical Hodgkin lymphoma","volume":"28","author":"Gopal","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/nature21026","article-title":"Corrigendum: PI3K\u03b3 is a molecular switch that controls immune suppression","volume":"542","author":"Kaneda","year":"2017","journal-title":"Nature"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20554","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells","volume":"539","author":"Rausch","year":"2016","journal-title":"Nature"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/jmv.25381","article-title":"Epstein-Barr virus LMP2A utilizes Syk and PI3K to activate NF-\u03baB in B-cell lymphomas to increase MIP-1\u03b1 production","volume":"91","author":"Incrocci","year":"2019","journal-title":"J. Med. Virol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/ijc.10845","article-title":"Hodgkin\u2019s lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2","volume":"103","author":"Joos","year":"2003","journal-title":"Int. J. Cancer"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.3324\/haematol.12875","article-title":"Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin\u2019s lymphoma by array-based comparative genomic hybridization","volume":"93","author":"Hartmann","year":"2008","journal-title":"Haematologica"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1182\/blood-2010-06-291310","article-title":"JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma","volume":"117","author":"Cox","year":"2011","journal-title":"Blood"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3324\/haematol.2017.180554","article-title":"A phase II study of the oral JAK1\/JAK2 inhibitor ruxolitinib in advanced relapsed\/refractory Hodgkin lymphoma","volume":"103","author":"Gastinne","year":"2018","journal-title":"Haematologica"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1073\/pnas.1524668113","article-title":"Augmented efficacy of brentuximab vedotin combined with ruxolitinib and\/or Navitoclax in a murine model of human Hodgkin\u2019s lymphoma","volume":"113","author":"Ju","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood-2017-10-812701","article-title":"Phase 1 study of the PI3K\u03b4 inhibitor INCB040093 \u00b1 JAK1 inhibitor itacitinib in relapsed\/refractory B-cell lymphoma","volume":"132","author":"Phillips","year":"2018","journal-title":"Blood"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/j.1365-2559.1987.tb01869.x","article-title":"Expression of lymphoid-associated antigens on Hodgkin\u2019s and Reed-Sternberg cells of Hodgkin\u2019s disease. An immunocytochemical study on lymph node cytospins using monoclonal antibodies","volume":"11","author":"Falini","year":"1987","journal-title":"Histopathology"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"7701","DOI":"10.1158\/1078-0432.CCR-09-1421","article-title":"A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma","volume":"15","author":"Dancey","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"13045","DOI":"10.1073\/pnas.1516107112","article-title":"90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin\u2019s lymphoma","volume":"112","author":"Janik","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_134","first-page":"1510","article-title":"Interim results from a phase 1 study of ADCT-301 (Camidanlumab Tesirine) show promising activity of a novel pyrrolobenzodiazepine-based antibody drug conjugate in relapsed\/refractory hodgkin\/non-hodgkin lymphoma","volume":"131","author":"Horwitz","year":"2017","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/asheducation.V2012.1.328.3798326","article-title":"New insights in the biology of Hodgkin lymphoma. Hematol","volume":"2012","year":"2012","journal-title":"Am. Soc. Hematol. Educ. Program"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/21\/5503\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:31:55Z","timestamp":1760189515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/21\/5503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,5]]},"references-count":136,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2019,11]]}},"alternative-id":["ijms20215503"],"URL":"https:\/\/doi.org\/10.3390\/ijms20215503","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,5]]}}}